As part of the ongoing fight against opioid abuse, Purdue Pharma has launched www.teamagainstopioidabuse.com, a new website that provides information on opioid abuse deterrence.

Roche is offering a rebate program for Accu-Chek test strips for Medicaid FPS and Medicare Part B beneficiaries.

Dear Valued Provider,

Effective August 5, 2016, Blue Cross and Blue Shield of North Carolina changed Crestor from Tier 1 or 2 to Tier 3 or 4 drug depending on the Covered Person’s benefits. This change is due to multiple new generic versions of Crestor (rosuvastatin calcium) being available on the market. If a Participating Pharmacy submits a claim for Crestor for a Covered Person, the claim will process at a tier 3 or 4 copayment compared to a Tier 1 or 2 copayment for rosuvastatin calcium.

For questions about coverage of Crestor or the generic products, please refer patients to the Customer Service number on the back of their Blue Cross ID card.

If you have any questions about claims processing, please call the Prime Contact Center at 800.821.4795. Sincerely,

Pharmacy Network Management

Prime Therapeutics LLC

* Coverage of Crestor is dependent on the Covered Persons’ benefit plan

Dear Valued Provider, Early May 2016, generic Crestor ® (rosuvastatin) became available in the market. Rosuvastatin remained Non-Formulary for Medicare Part D Covered Persons during a generic exclusivity period. Now that there are multiple generics available on the market, rosuvastatin will be available on the Medicare Part D formularies effective as of 8/10/2016. The innovator product Crestor will continue to be covered without prior approval* from the plan. Action Required If Participating Pharmacies receive a prescription for Crestor or for rosuvastatin for a Medicare Part D Covered Person, either product will result in a paid claim*. For Covered Persons who previously were only able to get Crestor, they will now have access to rosuvastatin without needing an authorization approved by the plan. For questions regarding coverage of Crestor ® or rosuvastatin, please refer Covered Persons to the Customer Service number on the back of their insurance card. If you have any questions regarding claims processing, please call the Prime Contact Center at 800.821.4795. Sincerely, Participating Pharmacy Network Management Prime Therapeutics LLC

Notice to Pharmacies

On June 1, 2016 the Centers for Medicare & Medicaid Services (CMS) issued an informational bulletin about Medicaid benefits available for the prevention, detection, and response to the Zika virus. Zika can cause severe birth defects in unborn children whose mothers are infected while pregnant. Because there is not a vaccine to prevent the disease or medicine to treat it, it is important for women to use repellent to protect themselves and unborn babies.

Starting August 9, 2016, Texas will cover select mosquito repellents under the Medicaid Fee For Service (FFS) and managed care organizations (MCO), Children's Health Insurance Plan (CHIP) and Healthy Texas Women programs. Neither the Kidney Health Care (KHC) nor Children with Special Health Care Needs (CSHCN) Services programs will cover these products. The following information describes the benefit details, including eligibility, benefit specifics, and claims processing and information about Zika virus.